Nitroglycerin + hydralazine in CHF patients is beneficial in african americans, but it’s effect in other racial and ethnic groups is less clear. In the retrospective cohort of CHF patients admitted with acute decompensated CHF (with cardiac index <2.2), researchers compared outcomes in those discharged on ACE/ARB, versus those discharged on ACE/ARB combined with isosorbide dinitrate + hydralazine (I/H group). Those in the I/H group had lower all cause mortality (34% versus 41%), and lower mortality/CHF readmissions (70% versus 85%). The benefit was found irrespective of race. I/H addition to ARB/ACE in CHF is associated with lower mortality (abstract).
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]
By reading the headlines recently, practitioners would not know if they saved or tanked the healthcare system. One day disaster looms, the next we have moderated growth and business can continue as usual (and by business, I mean doing the correct things correctly). A new study, along with some recent data, helps shed some light […]